Evotec SE 2010 AR2
The report highlights Evotec's financial and operational performance for the fiscal year 2010, marking its first profitable year in over 15 years of history. The company achieved a 29% revenue growth to €55.3 million, driven by strong performance in its discovery alliances and significant milestones, particularly with Boehringer Ingelheim. Key strategic developments included the acquisition of DeveloGen AG, which expanded Evotec's capabilities into metabolic diseases and regenerative medicine, and a major diabetes alliance with MedImmune. Additionally, Evotec successfully partnered its insomnia drug candidate, EVT 201, with Jingxin Pharma for development in China.
Company: Evotec SE
Sector: Manufacturing
Country: Germany
Year: 2010
Type: AR2
Pages: 104
Back to company
Evotec SE
Annual Report
The report highlights Evotec's financial and operational performance for the fiscal year 2010, marking its first profitable year in over 15 years of history. The company achieved a 29% revenue growth to €55.3 million, driven by strong performance in its discovery alliances and significant milestones, particularly with Boehringer Ingelheim. Key strategic developments included the acquisition of DeveloGen AG, which expanded Evotec's capabilities into metabolic diseases and regenerative medicine, and a major diabetes alliance with MedImmune. Additionally, Evotec successfully partnered its insomnia drug candidate, EVT 201, with Jingxin Pharma for development in China.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2010
Reporting Period
Jan 1, 2010 - Dec 31, 2010
Fiscal Year
2010
Published
Mar 24, 2011
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees